• Reuters

    US FDA puts partial clinical hold on BioNTech's early-stage study of cancer drug

    The drug, an antibody-drug conjugate (ADC), was being studied in a trial sponsored by China-based MediLink, in patients with types of non-small cell lung cancer or breast cancer who have received prior forms of treatment. ADCs, often described as "guided-missile" cancer drugs, are designed to target only cancer cells, unlike conventional chemotherapy, potentially reducing damage to normal cells. The U.S. health regulator has shared with MediLink concerns that the drug, BNT326/YL202, may, at higher doses, expose humans to unreasonable and significant risk of illness or injuries.

  • The Weather Network

    Which sunscreen should you choose? It depends on the weather

    Sunscreen is for all seasons and all types of conditions. Here's how to choose the right sun protection for your activity and time of year.

  • BBC

    Torrential rains trigger deadly landslides in Ecuador

    At least six people have died in mudslides triggered by heavy rain in central Ecuador.